Table 3. Numbers and odds ratios (OR) of severe maternal morbidity, maternal mortality, blood loss and transfusions after first line therapy according to TXA administration.
| Early TXA n = 247 |
Late/No TXA n = 984 |
Crude OR (95% CI) or crude difference | Adjusted OR (95% CI) or difference* | |
|---|---|---|---|---|
| Maternal mortality | 2 (0,8) | 4 (0,4) | 2,00 (0,36–10,98) | 1,31 (0,20–8,73) |
| Hysterectomy/ligation arteries/ B-lynch | 28 (11,2) | 68 (6,7) | 1,71 (1,07–2,75) | 1,10 (0,63–1,95) |
| Embolization | 33 (13,1) | 132 (13,1) | 1,00 (0,66–1,52) | 0,76 (0,48–1,22) |
| ICU admission | 75 (29,9) | 287 (28,4) | 1,07 (0,78–145) | 0,85 (0,60–1,19) |
| Composite morbidity mortality† | 96 (38,2) | 345 (34,2) | 1,21 (0,90–1,61) | 0,92 (0,66–1,27) |
| Additional blood loss after first line therapy (mL)‡ | 2150 (1058–3115) | 2100 (1244–3001) | +145,7 (-167,1–458,5) | -177,2§ (-509,4–155,0) |
| Total units of RBC ǁ | 4 (2–6) | 4 (3–5) | 0,35 (-0,20–0,90) | -0,73 (-1,35–0,10) |
| Total units of FFP | 2 (2–4) | 2 (2–3) | 0,56 (0,17–0,95) | -0,12 (-0,55–0,31) |
| Total units of platelets | 1 (1–2) | 1 (1–2) | -0,03 (-0,42–0,36) | -0,40 (-0,80–0,00) |
| Total units of blood products | 6 (4–10) | 6 (4–8) | 1,33 (0,33–2,32) | -0,62 (-1,72–0,48) |
*ORs and differences were adjusted for pre-defined confounders: bleeding rate, measured blood loss, fluids and blood products administered at first line therapy; Occurrence of shock before first line therapy, primary cause of major obstetric haemorrhage abnormal placentation, maternal age, mode of delivery, previous administration of fibrinogen and rec FVIIa. Multiple imputation was used.
† Patients that reached at least one of the predefined clinical endpoints (maternal mortality, hysterectomy/B-lynch/arterial ligation, embolization, ICU admission.
‡ Blood loss in ml, median & IQR are reported
§ Difference between groups calculated by linear regression analysis
ǁ Median and IQR are reported